Skip to main content
Back to feed
HealthReportedLow
2.1

Brazil's Anvisa approves Ordexa, lisdexamfetamine-based ADHD drug

Brazil's health regulator Anvisa approved Ordexa, a lisdexamfetamine dimesylate-based medicine for ADHD, in 30/50/70 mg doses. This expands domestic treatment options but is a routine regulatory approval with no immediate market or geopolitical impact.

Poder3603 days agoBRCredibility 41%View source

Score Breakdown

Mosaic Score2.1
Model confidence0.9
Significance0.1
Source credibility0.4

Intelligence Tags

#adhd#drug-approval#brazil#anvisa#pharmaceuticals

Entities

country
Source

Related signals

8 found